New Shareholders joining AMW GmbH to Catalyze Long-term Growth Strategy Following Another Year of Record Sales

Ren Life Sciences, a specialist investment firm focused on advancing European life-sciences, and Juno Capital Partners, a global specialist company in the pharmaceuticals market based in Toronto, Canada, took over from existing shareholders Bayern Kapital, BayBG, KfW, UVC Partners and bmp Ventures with IBG funds to become new majority shareholders of AMW GmbH. Two existing shareholders remain invested: SHS Capital, a European healthcare growth investor, who was the first investor in AMW GmbH, as well as AMW Evolution, an investment vehicle representing the Company’s Chairman of the Board, the CEO, management and employees. SHS Capital exited its investment in AMW GmbH through a prior fund and re-invested through its current fund.
“We are delighted to welcome our new partners. Bringing Ren Life Sciences and Juno Capital Partners on board, and continuing our partnership with SHS Capital, is the perfect set-up for securing our long-term growth,” said Philipp Karbach, CEO and shareholder of AMW GmbH. “After another year of record sales in 2025, I am excited to partner with their seasoned teams to take even bigger steps towards becoming a global leader in the development, manufacturing and distribution of biodegradable controlled-release drug delivery systems. I would like to express my sincere gratitude to our departing investors, and to our longstanding financing partners such as the European Investment Bank (EIB), who have supported AMW with full commitment over the past years and significantly contributed to shaping the Company.”
“Ren Life Sciences, Juno Capital Partners and SHS Capital are ideal partners to accelerate AMW’s growth strategy,” said Dr. Martin Zügel, Chairman of the Board and Managing Director of AMW Evolution. “We’re pleased to have secured experienced international growth investors with a strong track record in building global pharma champions – exactly the right partners for AMW’s next chapter. I would like to thank the departing investors for their long-standing support and perseverance over many years.”

About AMW GmbH
AMW GmbH is a specialty pharmaceutical company focused on biodegradable implants, providing patients and partners access to value-added medicines for improved adherence and cost-effective therapies. The Company covers the entire value chain, from (co-)development to manufacturing and international commercialization.
AMW GmbH has two approved pharmaceutical products: implants releasing goserelin or leuprorelin respectively, which are distributed worldwide via direct sales and out-licensing. In Germany, leuprorelin is marketed as Leugon® by AMW’s fully owned subsidiary Endomedica GmbH. Based on its unparalleled expertise in formulation development, the Company collaborates with pharma and biotech partners worldwide to develop and manufacture high-quality products and life-cycle solutions.
AMW GmbH is based in Warngau near Munich, Germany.

About AMW Evolution
Founded in 2021, AMW Evolution is a special purpose vehicle combining shares of AMW GmbH held by the Chairman of the Board, the CEO, members of the management team and interested employees of AMW GmbH and its 100% subsidiary Endomedica GmbH.

About bmp Ventures
bmp Ventures is one of the most experienced venture capital investors in Germany, with a track record of more than 250 investments across nearly all technology segments, the majority of which are in the early stage. In addition to direct investments, bmp has also managed venture capital funds for the KfW Banking Group and DEG – Deutsche Investitions- und Entwicklungsgesellschaft. Currently, bmp manages the IBG funds in Saxony-Anhalt and employs around 20 people at its offices in Berlin and Magdeburg.

About the IBG Funds
The IBG Funds, based in Magdeburg, are the venture capital funds of the State of Saxony-Anhalt. They provide equity financing to young, innovative technology companies with above-average growth potential that are headquartered in Saxony-Anhalt. At the end of 2023, the new venture capital fund RKF IV was launched with a total volume of €63 million. It is financed by the State of Saxony-Anhalt and the European Union and invests in startups in the seed, early-stage, and growth phases. The IBG Funds are managed by bmp Ventures AG.

Press Contact

AMW GmbH
Eva Hoffmann
Phone: +49 8024 470999-0
news@amw-pharmaceuticals.com

bmp Ventures AG
Josephine Gantze
Marketing & Events
Tel.: +49 391 5328 140
jgantze@bmp.com

All image rights are owned by AMW GmbH.